These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 8725726)
1. Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids. Valentin S; Schousboe I Thromb Haemost; 1996 May; 75(5):796-800. PubMed ID: 8725726 [TBL] [Abstract][Full Text] [Related]
2. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes. Willems GM; Janssen MP; Salemink I; Wun TC; Lindhout T Biochemistry; 1998 Mar; 37(10):3321-8. PubMed ID: 9521652 [TBL] [Abstract][Full Text] [Related]
3. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor. Iakhiaev A; Ruf W; Rao LV Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815 [TBL] [Abstract][Full Text] [Related]
4. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716 [TBL] [Abstract][Full Text] [Related]
5. The importance of the binding of factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor: the transmembrane and cytoplasmic domains of tissue factor are not essential for the inhibitory action of tissue factor pathway inhibitor. Kazama Y Thromb Haemost; 1997 Mar; 77(3):492-7. PubMed ID: 9066000 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation. Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212 [TBL] [Abstract][Full Text] [Related]
7. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Salemink I; Franssen J; Willems GM; Hemker HC; Li A; Wun TC; Lindhout T Thromb Haemost; 1998 Aug; 80(2):273-80. PubMed ID: 9716152 [TBL] [Abstract][Full Text] [Related]
8. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes. Li A; Chang AC; Peer GT; Wun TC; Taylor FB Thromb Haemost; 2001 May; 85(5):830-6. PubMed ID: 11372676 [TBL] [Abstract][Full Text] [Related]
9. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa. Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408 [TBL] [Abstract][Full Text] [Related]
10. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Cunningham AC; Hasty KA; Enghild JJ; Mast AE Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418 [TBL] [Abstract][Full Text] [Related]
11. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Valentin S; Nordfang O; BregengÄrd C; Wildgoose P Blood Coagul Fibrinolysis; 1993 Oct; 4(5):713-20. PubMed ID: 8292720 [TBL] [Abstract][Full Text] [Related]
12. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Piro O; Broze GJ Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366 [TBL] [Abstract][Full Text] [Related]
13. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor. Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974 [TBL] [Abstract][Full Text] [Related]
14. Tissue factor pathway inhibitor; its structure, function and clinical significance. Kato H Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa. Valentin S; Reutlingsperger CP; Nordfang O; Lindhout T Thromb Haemost; 1995 Dec; 74(6):1478-85. PubMed ID: 8772224 [TBL] [Abstract][Full Text] [Related]
17. Protein S is a cofactor for tissue factor pathway inhibitor. Rosing J; Maurissen LF; Tchaikovski SN; Tans G; Hackeng TM Thromb Res; 2008; 122 Suppl 1():S60-3. PubMed ID: 18691502 [TBL] [Abstract][Full Text] [Related]
18. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa. Peraramelli S; Suylen DP; Rosing J; Hackeng TM Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666 [TBL] [Abstract][Full Text] [Related]
19. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies. Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186 [TBL] [Abstract][Full Text] [Related]
20. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]